Gefitinib, erlotinib and afatinib are three widely used epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR TKIs) for treating advanced non‐small cell lung cancer …

The identification of Epidermal Growth Factor Receptor (EGFR) mutations in lung
adenocarcinoma has facilitated the development of personalized medicine based on …

Background Afatinib 40 mg/day is approved for first-line treatment of EGFR mutation-positive
non-small-cell lung cancer (NSCLC). In the case of drug-related grade≥ 3 or selected …

Background Afatinib is a second-generation epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor (TKI). Compared to cytotoxic chemotherapy, afatinib has been …

Thyroid cancer is the most common endocrine malignancy, with over 60,000 cases reported
per year in the US alone. The incidence of thyroid cancer has increased in the last several …

Background Epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs) are
standard treatments for advanced non–small cell lung cancer (NSCLC) patients harboring …

Background The first-generation epidermal growth factor receptor tyrosine kinase inhibitors
gefitinib and erlotinib have both been proven effective for treating advanced non–small cell …

Background Rash is a well-known predictor of survival for patients with gefitinib therapy with
non-small cell lung cancer (NSCLC). However, whether patients with more severe rash …

Introduction: Understanding the mechanism of DILI with MTA, and how to avoid and manage
these toxicities is essential for minimising inferior cancer treatment outcomes. An organised …

Background The use of oral systemic anticancer therapies (SACT) has increased and led to
improved cancer survival outcomes, particularly with the introduction of small molecule …